Pharmaceutial & Healthcare

 The global polycystic ovarian syndrome (PCOS) treatment market size is expected to value at USD 5.1 billion by 2025. The market is subject to witness a substantial growth due to the easy identification of symptoms associated with this syndrome, and easy accessibility to a range of drug essential for the treatment. Furthermore, substantial focus on the development of the drug to find permeant solution involving complete cure for the polycystic ovarian syndrome (PCOS) and rising investment by industry players for research development of drugs are some of the critical factors expected to fuel growth of the PCOS treatment market during the forecast period. Globally, the market is predicted to grow at CAGR of 5.0% in forecast period, providing numerous opportunity for market players to invest for research and development in the polycystic ovarian syndrome (PCOS) treatment market. Currently, no particular medication has been developed for treatment of PCOS treatment market. Thus, symptoms d

 The global Xerostomia (Dry Mouth) Therapeutics Market is anticipated to reach USD 796.1 million and is anticipated to grow at a CAGR of 3.2% in the years to come. Xerostomia is a clinical condition of dry mouth and does not show the signs of hyposalivation and symptoms on frequent terms. This condition is observed when the rate of saliva flow is low in comparison with absorption across the oral mucosa coupled with rate of fluid evaporation from the mouth. Prolonged xerostomia is a significant disease in patients since it affects speech, chewing, denture-wearing, and swallowing activities. The defined causes of hyposalivation and xerostomia are the use of several medications such as antidepressants, anticoagulants, antiretroviral, hypoglycemics, multivitamins and supplements, and anti-inflammatory drugs. Prevalence of xerostomia persists in a large population with different age groups despite following medical or dental consultation. Rise in use of prescribed medication coupled with ri